Procter & Gamble Health growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY27Jun 2026FY26Jun 2025FY25Jun 2024FY23 and earlierAlpha Plus
+7.4%−70.6%−6.4%
FY23 and earlierEvery year the company has filed comes with Alpha Plus.
+10.3%−70.5%−5.5%
+10.2%−69.5%−6.1%
+45.3%−67.1%−12.4%
+45.3%−67.1%−12.4%
——−27.9%
——−28.3%
——−3.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

PGHL₹5,513.50

Procter & Gamble Health Limited

· Pharma & Health
₹ CrorePeersSANOFICONRSANOFISENORESINNOVACAPMOREPENLABIOLCPFDCASTRAZENMcap ₹9,152 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
30/06/2023
FY25
30/06/2024
FY26
30/06/2025
FY27
30/06/2026
Revenue Growth—-6.4-70.6+7.4
EBITDA Growth—-5.5-70.5+10.3
EBIT Growth—-6.1-69.5+10.2
Net Income Growth—-12.4-67.1+45.3
EPS Growth—-12.4-67.1+45.3
Total Assets Growth—-27.9——
Total Equity Growth—-28.3——
Cash from Operations Growth—-3.3——
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY27 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.